BACKGROUND: Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are approved for venous thromboembolism (VTE) prophylaxis. Which agent is superior remains controversial.

Tinzaparin is a low-molecular-weight heparin (LMWH) with antithrombotic properties. It has FDA-approved labeling for use in the treatment of acute symptomatic deep-vein thrombosis (DVT ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

Although low-molecular-weight heparin (LMWH) has been recommended to prevent venous thromboembolism, its anticoagulant and anti-inflammatory effects in sepsis remain controversial. Owing to the ...

Pregnancy brings dramatic changes to a woman's vascular system, with potentially serious health implications for both mother ...

The existing evidence suggests that low molecular weight heparin (LMWH) has effects beyond its antithrombotic action, improving placental microvessel structure and function of pregnant women with ...

low-molecular-weight heparin, to prevent life-threatening blood clots. A new clinical trial, however, found that ... Nov. 7, 2022 — A new study could change the treatment course for hundreds of ...

The initial differential diagnosis included pulmonary embolus and therefore treatment dose low molecular weight heparin was given and a CT pulmonary angiogram (CTPA) was arranged. The CTPA did not ...

Consider whether there is a real need to stop anticoagulation for the scheduled procedure. Do not use low molecular weight heparin (LMWH) to bridge direct oral anticoagulants. Do not use therapeutic ...